Market Overview

UPDATE: Oppenheimer Initiates Laboratory Corporation of America Holdings at Perform on Industry Headwinds

Related LH
Deutsche Bank Offers Up A Pair Trade Idea On Quest Diagnostics & Laboratory Corp. of America
Benzinga's Top Downgrades

Oppenheimer initiated coverage on Laboratory Corporation of America Holdings (NYSE: LH) with a Perform rating.

Oppenheimer commented, "As the most efficient testing provider, we believe LH is best positioned to absorb the mandated reimbursement cuts and expected future cuts. We also view the company's esoteric business with the acquired genetic counselors as a key point of differentiation. With that said, the industry headwinds cause us to rate the shares Perform. In particular, we believe the 2% sequestration cut will likely be expanded. On the volume front, our survey work points to hospitals continuing to shift volume to their own outpatient and outreach labs. The company's strong cash provides flexibility to deliver shareholder value but we await the results of round two of the fiscal cliff negotiations."

Laboratory Corporation of America Holdings closed at $88.66 on Monday.

Latest Ratings for LH

DateFirmActionFromTo
Nov 2014Deutsche BankDowngradesBuyHold
Nov 2014Deutsche BankMaintainsBuy
Oct 2014JP MorganMaintainsNeutral

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Initiation Analyst Ratings

 

Related Articles (LH)

Around the Web, We're Loving...

Get Benzinga's Newsletters